deltatrials
Completed PHASE3 INTERVENTIONAL 5-arm NCT04324463

Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) Trial (ACTCOVID19)

Anti-Coronavirus Therapies to Prevent Progression of COVID-19, a Randomized Trial

Sponsor: Bayer

Updated 19 times since 2020 Last updated: Jan 10, 2024 Started: Apr 21, 2020 Primary completion: Dec 30, 2022 Completion: Dec 30, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04324463, this PHASE3 trial focuses on Coronavirus and Severe Acute Respiratory Syndrome and remains completed. Sponsored by Bayer, it has been updated 19 times since 2020, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Apr 2020 – ~May 2020 · 30 days · monthly snapshot~May 2020 – ~Jul 2020 · 2 months · monthly snapshot~Jul 2020 – ~Oct 2020 · 3 months · monthly snapshot~Oct 2020 – ~Nov 2020 · 31 days · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Jun 2021 · 5 months · monthly snapshot~Jun 2021 – ~Feb 2022 · 8 months · monthly snapshot~Feb 2022 – ~Apr 2022 · 59 days · monthly snapshot~Apr 2022 – ~Sep 2022 · 5 months · monthly snapshot~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Feb 2023 · 3 months · monthly snapshot~Feb 2023 – ~Jun 2023 · 4 months · monthly snapshot~Jun 2023 – ~Sep 2023 · 3 months · monthly snapshot~Sep 2023 – ~Dec 2023 · 3 months · monthly snapshot~Dec 2023 – ~Feb 2024 · 2 months · monthly snapshot~Feb 2024 – ~Jul 2024 · 5 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 9 months · monthly snapshot

Change History

19 versions recorded
  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Feb 2024 — Jul 2024 [monthly]

    Completed PHASE3

    Status: Active Not RecruitingCompleted

  5. Dec 2023 — Feb 2024 [monthly]

    Active Not Recruiting PHASE3

Show 14 earlier versions
  1. Sep 2023 — Dec 2023 [monthly]

    Active Not Recruiting PHASE3

  2. Jun 2023 — Sep 2023 [monthly]

    Active Not Recruiting PHASE3

  3. Feb 2023 — Jun 2023 [monthly]

    Active Not Recruiting PHASE3

  4. Nov 2022 — Feb 2023 [monthly]

    Active Not Recruiting PHASE3

  5. Sep 2022 — Nov 2022 [monthly]

    Active Not Recruiting PHASE3

  6. Apr 2022 — Sep 2022 [monthly]

    Active Not Recruiting PHASE3

    Status: RecruitingActive Not Recruiting

  7. Feb 2022 — Apr 2022 [monthly]

    Recruiting PHASE3

  8. Jun 2021 — Feb 2022 [monthly]

    Recruiting PHASE3

  9. Jan 2021 — Jun 2021 [monthly]

    Recruiting PHASE3

  10. Nov 2020 — Jan 2021 [monthly]

    Recruiting PHASE3

  11. Oct 2020 — Nov 2020 [monthly]

    Recruiting PHASE3

  12. Jul 2020 — Oct 2020 [monthly]

    Recruiting PHASE3

  13. May 2020 — Jul 2020 [monthly]

    Recruiting PHASE3

    Status: Not Yet RecruitingRecruiting

  14. Apr 2020 — May 2020 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Bayer
  • Population Health Research Institute
Data source: Population Health Research Institute

For direct contact, visit the study record on ClinicalTrials.gov .